Human epidermal growth factor receptor-2-positive breast cancer: Does estrogen receptor status define two distinct subtypes?

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 283-291

  Vaz Luis, I ^a,b   Winer, E P ^a   Lin, N U ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Breast cancer; Estrogen receptor; Human epidermal growth factor receptor 2; Outcomes; Subtypes

Indexed keywords

ANASTROZOLE; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; METASTASIS; MOLECULAR INTERACTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW;

EID: 84873881934     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds286     Document Type: Review

References (91)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
3. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/ neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003; 95: 142-153.
4. Marsigliante S, Muscella A, Ciardo V et al. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades. Cancer Lett 1993; 75: 195-206.
5. Dabbs DJ, Klein ME, Mohsin SK et al. High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 2011; 29: 4279-4285.
6. Baehner FL, Achacoso N, Maddala T et al. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol 2010; 28: 4300-4306.
7. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28(16):2784-2795.
8. Hammond ME, Hayes DF, Wolff AC. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol 2011; 29: e458.
9. Badve SS, Baehner FL, Gray RP et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008; 26: 2473-2481.
10. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
11. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
12. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
13. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
14. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009; 69: 4116-4124.
15. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
16. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
17. Korkaya H, Paulson A, Iovino F et al. HER2 regulates the mammary stem/ progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27: 6120-6130.
18. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
19. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.
20. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2010; 5: 5-23.
21. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
22. Marchio C, Natrajan R, Shiu KK et al. The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 2008; 216: 399-407.
23. Staaf J, Jonsson G, Ringner M et al. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 2010; 12: R25.
24. Bianchini G, Prat A, Pickl M et al. Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: gene expression analysis [abstract]. J Clin Oncol 2011; 29(Suppl): a529.
25. Gianni L, Bianchini G, Kiermaier A et al. Neoadjuvant pertuzumab and trastuzumab: biomarker analyses of a 4-arm randomized phase II study (NeoSphere) in patients with HER2-positive breast cancer [abstract]. Cancer Res 2011; 71(Suppl 24):a109s.
26. Saal LH, Holm K, Maurer M et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554-2559.
27. Niemeier LA, Dabbs DJ, Beriwal S et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010; 23: 205-212.
28. Park S, Koo J, Park HS et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010; 21: 488-492.
29. Collins LC, Cole KS, Marotti JD et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2011; 24: 924-931.
30. Lin Fde M, Pincerato KM, Bacchi CE et al. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity. J Clin Pathol 2011; 65: 64-68.
31. Peters AA, Buchanan G, Ricciardelli C et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009; 69: 6131-6140.
32. Hu R, Dawood S, Holmes MD et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 2011; 17: 1867-1874.
33. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25: 3994-4008.
34. Ni M, Chen Y, Lim E et al. Targeting androgen receptor in estrogen receptornegative breast cancer. Cancer Cell 2011; 20: 119-131.
35. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2011; 13: 25-32.
36. Massarweh S, Osborne CK, Jiang S et al. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 2006; 66: 8266-8273.
37. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935.
38. Wang YC, Morrison G, Gillihan R et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011; 13: R121.
39. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21: 46-53.
40. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685.
41. Eiermann W, Baselga J, Semiglazov V et al. Hormone-receptor status and likelihood of predicting pathological complete response in the NOAH trial of neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer [abstract]. Eur J Cancer, 2008; 67(Suppl 115): a228.
42. Untch M, Rezai M, Loibl S et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28: 2024-2031.
43. Guarneri V, Frassoldati A, Bottini A et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial) [abstract]. J Clin Oncol 2011; 29(Suppl): a507.
44. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-40.
45. Gee JM, Hutcheson IR, Knowlden JM et al. The EGFR-selective tyrosine kinase inhibitor ZD 1839 (Iressa) is an effective inhibitor of tamoxifen-resistant breast cancer growth [abstract]. Proc Am Soc Clin Oncol 2001; 20: 71a.
46. Ali S, Metzger D, Bornert JM et al. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J 1993; 12: 1153-1160.
47. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000; 20: 5041-5047.
48. Arpino G, Gutierrez C, Weiss H et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 2007; 99: 694-705.
49. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537.
50. Johnston S, Pippen J, Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptorpositive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
51. Chang JCN, Mayer IA, Forero-Torres A et al. TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer [abstract]. J Clin Oncol 2011; 29(Suppl): a505.
52. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
53. Guarneri V, Broglio K, Kau SW et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-1044.
54. Ring AE, Smith IE, Ashley S et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004; 91: 2012-2017.
55. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
56. Mazouni C, Kau SW, Frye D et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 2007; 18: 874-880.
57. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
58. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
59. Kim SI, Sohn J, Koo JS et al. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology 2011; 79: 324-330.
60. Darb-Esfahani S, Loibl S, Muller BM et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Res 2009; 11: R69.
61. Von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-804.
62. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
63. Untch M, Gelber RD, Jackisch C et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19: 1090-1096.
64. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
65. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. J Am Med Assoc 2006; 295: 1658-1667.
66. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-2313.
67. Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in nodepositive breast cancer. N Engl J Med 2007; 357: 1496-1506.
68. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
69. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-3373.
70. Kennecke H, Yerushalmi R, Woods R et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28: 3271-3277.
71. Vaz-Luis I, Ottesen R, Hughes M et al. Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the national comprehensive cancer network (NCCN) [abstract]. J Clin Oncol 2012; 30(Suppl): a599.
72. Hess KR, Pusztai L, Buzdar AU et al. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003; 78: 105-118.
73. Park YH, Lee S, Cho EY et al. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol 2010; 66: 507-16.
74. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 1989; 8: 98-101.
75. Kang Y, Siegel PM, Shu W et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-549.
76. Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
77. Bos PD, Zhang XH, Nadal C et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005-1009.
78. Klein A, Olendrowitz C, Schmutzler R et al. Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett 2009; 276: 212-220.
79. Brufsky A, Lembersky B, Schiffman K et al. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 2005; 6: 247-252.
80. Bayo-Calero JL, Mayordomo JI, Sanchez-Rovira P et al. A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. Clin Breast Cancer 2008; 8: 264-268.
81. Wardley AM, Pivot X, Morales-Vasquez F et al. Randomized phase II trial of firstline trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 2009; 28: 976-983.
82. Schilling G, Bruweleit M, Harbeck N et al. Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy). Invest New Drugs 2009; 27: 166-172.
83. Kaufman PA, Mayer M, Paik S et al. registHER: trastuzumab-based taxane or vinorelbine treatment selection in patients with HER2/neu-positive metastatic breast cancer: patient characteristics and preliminary outcomes [abstract]. In San Antonio Breast Cancer Symposium, 2006, Suppl, a2066.
84. Finn RS, Press MF, Dering J et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 2009; 27: 3908-3915.
85. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
86. Metro G, Giannarelli D, Gemma D et al. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. Breast J 2010; 16: 66-72.
87. von Minckwitz G, Schwedler K, Schmidt M et al. Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011; 47: 2273-2281.
88. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28: 1138-44.
89. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-19.
90. Arteaga CL, O'Neill A, Moulder SL et al. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 2008; 14: 6277-83.
91. Lu X, Wang ZC, Iglehart JD et al. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 2008; 108: 191-201.